Antti has provided his preliminary comments ahead of Orion’s Q2 earnings report this Friday 
We expect the company to report very strong revenue and earnings growth once again, driven by the strong global demand for the prostate cancer drug Nubeqa. Although we expect some segments to face tough comparison figures, the group-level performance currently rests solidly on the success of Nubeqa and the high-margin royalty stream it generates.